Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A FULLY INTEGRATED ASSAY AND PLATFORM FOR DETECTING CLOSTRIDIUM DIFFICILE

Award Number: R43AI078619
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2009
PERIOD OF PERFORMANCE END DATE: 07/31/2011

Group Awards By:

View Award Description

A FULLY INTEGRATED ASSAY AND PLATFORM FOR DETECTING CLOSTRIDIUM DIFFICILE - DESCRIPTION (provided by applicant): Antibiotic treatment of infections with harmful bacteria can destroy the normal colonic flora, and increase the patient's susceptibility to Clostridium difficile-associated disease (CDAD). Pathogenic strains of C. difficile commonly produce two large clostridial toxins, A (TcdA) and B (TcdB), responsible for CDAD. The TcdC gene is a negative regulator of the TcdA and TcdB genes, and the most highly virulent strain of C. difficile, BI/NAP1, has a single point mutation in this gene that results in a premature stop codon. The lack of a functional TcdC protein in these strains results in an over expression of the TcdA and TcdB toxins. This strain is associated with more severe morbidity and mortality in patients. Simple assays that are robust and specific for CDAD and in particular for the BI/NAP1 strain are needed to facilitate better diagnosis and treatment of C. difficile infected patients. The current, widely used, EIA tests are rapid but lack sensitivity whereas the more sensitive tests (cytotoxicity assay or C. difficile culture) require one or more days to complete. There is also clearly a need for a reliable, sensitive, and expeditious method for testing of environmental contamination. A sensitive assay that is capable of processing and detecting C. diff spores would substantially protect the health of the patient as well as reduce the risk of spread of CDAD in hospitals, nursing homes, and rehabilitation facilities. Most cases of remission are due to re-infection. Decontamination is very difficult and currently not supported by a reliable and sensitive method of verification. In this Phase I, we propose to develop a simple assay system for the detection of the TcdA gene, the TcdB gene and the TcdC point mutation using proprietary helicase-dependent amplification (HAD") technology. HDA reactions will detect TcdA for the presence and load of Clostridium difficile and TcdC D117 mutation for the presence of the highly virulent strain of C. difficile. We will develop a point-of-care (POC) instrument that will extract DNA from stool samples and environmental swabs. The sample processing methods selected for this plan are robust and simple, avoiding the need for wash steps, elution buffers, or centrifugation. This will be accomplished through the development of subsystem modules, each designed in a cartridge that is independently functional to its purpose, is disposable after one use, and can also be snapped together to the other modules for integrated function. This sample processing system will be integrated with the fluorimeter, a real-time fluorescent detection system that has been previously used with the HDA" assay method. PUBLIC HEALTH RELEVANCE: There is a clear clinical need for a rapid but sensitive test for C. difficile infection. The current, widely used, EIA tests are rapid but lack sensitivity whereas the more sensitive tests (cytotoxicity assay or C. difficile culture) require one or more days to complete. There is also clearly a need for a reliable, sensitive and expeditious method for testing for environmental contamination. A sensitive assay that is capable of processing and detecting C. diff spores would substantially protect the health of patients and reduce the cost of healthcare in hospitals, nursing homes and rehabilitation facilities. The goal of this project is to develop a point-of-care system for the detection of C. difficile.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $298,122 )
2010	2010	CLAREMONT BIOSOLUTIONS LLC	1616 NORTH LAUREL AVENUE	UPLAND	CA	91784	SAN BERNARDINO	USA	Allergy and Infectious Diseases Research	000	2	6/30/2010	NON-COMPETING CONTINUATION	$298,122
														Subtotal = $298,122

Issue Date FY: 2009 ( Subtotal = $311,184 )
2009	2009	CLAREMONT BIOSOLUTIONS LLC	1616 NORTH LAUREL AVENUE	UPLAND	CA	91784	SAN BERNARDINO	USA	Allergy and Infectious Diseases Research	000	1	7/24/2009	NEW	$311,184
														Subtotal = $311,184

Grand Total All Awards = $609,306

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A FULLY INTEGRATED ASSAY AND PLATFORM FOR DETECTING CLOSTRIDIUM DIFFICILE

Award Number: R43AI078619

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2009

PERIOD OF PERFORMANCE END DATE: 07/31/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer